Tangier disease gene therapy - CV Therapeutics
Latest Information Update: 16 Jul 2002
At a glance
- Originator CV Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tangier disease
Most Recent Events
- 29 Aug 2000 New profile
- 29 Aug 2000 Preclinical development for Tangier disease in USA (Unknown route)